MX2023004017A - Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. - Google Patents
Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.Info
- Publication number
- MX2023004017A MX2023004017A MX2023004017A MX2023004017A MX2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A MX 2023004017 A MX2023004017 A MX 2023004017A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- antibody
- crohn
- treating crohn
- dosing
- Prior art date
Links
- 208000011231 Crohn disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000012423 maintenance Methods 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos y composiciones para el tratamiento probado como seguro y efectivo de la enfermedad de Crohn, particularmente la enfermedad de Crohn activa de moderada a grave en pacientes, que comprenden dosis inicial intravenosa y dosis de mantenimiento subcutánea de un anticuerpo IL12/IL23p40 con intervalos de dosis de mantenimiento determinados mediante la evaluación de indicadores clínicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063089786P | 2020-10-09 | 2020-10-09 | |
US202163235188P | 2021-08-20 | 2021-08-20 | |
PCT/IB2021/059211 WO2022074603A1 (en) | 2020-10-09 | 2021-10-07 | Method for treating crohn's disease with anti-il12/il23 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004017A true MX2023004017A (es) | 2023-07-05 |
Family
ID=81078738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004017A MX2023004017A (es) | 2020-10-09 | 2021-10-07 | Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220112282A1 (es) |
EP (1) | EP4225350A1 (es) |
JP (1) | JP2023544620A (es) |
KR (1) | KR20230084283A (es) |
CN (1) | CN116348491A (es) |
AU (1) | AU2021356282A1 (es) |
CA (1) | CA3198413A1 (es) |
IL (1) | IL301944A (es) |
MX (1) | MX2023004017A (es) |
WO (1) | WO2022074603A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111471655B (zh) * | 2020-03-19 | 2023-07-07 | 湖州正熙医学检验实验室有限公司 | 抗人il12/23稳转细胞株及其构建方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020128864A1 (en) * | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
-
2021
- 2021-10-07 MX MX2023004017A patent/MX2023004017A/es unknown
- 2021-10-07 CA CA3198413A patent/CA3198413A1/en active Pending
- 2021-10-07 CN CN202180068739.4A patent/CN116348491A/zh active Pending
- 2021-10-07 WO PCT/IB2021/059211 patent/WO2022074603A1/en active Application Filing
- 2021-10-07 KR KR1020237015711A patent/KR20230084283A/ko unknown
- 2021-10-07 US US17/496,057 patent/US20220112282A1/en active Pending
- 2021-10-07 IL IL301944A patent/IL301944A/en unknown
- 2021-10-07 JP JP2023521437A patent/JP2023544620A/ja active Pending
- 2021-10-07 EP EP21877115.2A patent/EP4225350A1/en active Pending
- 2021-10-07 AU AU2021356282A patent/AU2021356282A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220112282A1 (en) | 2022-04-14 |
CN116348491A (zh) | 2023-06-27 |
IL301944A (en) | 2023-06-01 |
JP2023544620A (ja) | 2023-10-24 |
CA3198413A1 (en) | 2022-04-14 |
WO2022074603A1 (en) | 2022-04-14 |
KR20230084283A (ko) | 2023-06-12 |
EP4225350A1 (en) | 2023-08-16 |
AU2021356282A1 (en) | 2023-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003411A (es) | Metodo seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23. | |
SG170058A1 (en) | Methods of treating inflammatory and autoimmune diseases with natalizumab | |
MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
MY188825A (en) | High-concentration monoclonal antibody formulations | |
MX2022010483A (es) | Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus. | |
EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MX2023004017A (es) | Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23. | |
MX2022013923A (es) | Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23. | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
JP2013520447A5 (es) | ||
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
CN108392743A (zh) | 具有610-650nm波长的LED-红光在缓解腰肌劳损症状中的应用 | |
CR20220040A (es) | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab | |
MX2014013380A (es) | Usos de cxcl17, un nuevo marcador de quimiocinas de enfermedad pulmonar y gastrointestinal humana. | |
Suwansrinon et al. | Is injecting a finger with rabies immunoglobulin dangerous? | |
MX2022009987A (es) | Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. | |
Orlova et al. | THU0591 Comparative Efficacy of Two Exercises Programs in Patients with Early Rheumatoid Arthritis: 6-Month Randomized Controlled Trial | |
MX2022016174A (es) | Composiciones y metodos para tratar un trastorno obsesivo-compulsivo. | |
Recuenco et al. | Assessment of the growth inhibitory effect of gellan sulfate in rodent malaria in vivo | |
BR112022007314A2 (pt) | Método seguro e eficaz de tratamento de colite ulcerativa com anticorpos anti-il12/il23 | |
MX2022001154A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
Kong | Changes of Maximum Inspiratory Pressure, Maximum Expiratory Pressure, Back Mobility by Diaphragm Stretching Technique in Patients with Low Back Pain | |
Kaňovský et al. | Duration of treatment effect of incobotulinumtoxina (Xeomin) in upper limb spasticity |